Pharma Five is a registered firm based in India. We specialize in Named Patient Imports, Imported cancer drugs, Imported medicines in india.
Contact Us Pharma Five Door No. 74, Old No. 26, Fagun Mansion, 3rd Floor, Ethiraj Salai, Egmore, Chennai - 600008 +916374297988 info@pharmafive.org
Medicine name : Lumoxiti
Generic name : Moxetumomab
Manufactured By : Innate
Indications : Relapsed or refractory Hairy cell leukemia
Medicine Description : Lumoxiti is an anti-CD22 immunotoxin for relapsed or refractory hairy cell leukemia (HCL). It binds to cancer cells, delivering a toxin that induces cell death. Given via IV infusion, it provides targeted therapy. Side effects include capillary leak syndrome, kidney damage, and low blood counts. Fluid balance and kidney function monitoring are critical.
Lumoxiti (Moxetumomab pasudotox-tdfk) is a prescription medicine used to treat adults with relapsed or refractory hairy cell leukemia (HCL) after at least two prior systemic therapies, including a purine nucleoside analog.
Lumoxiti is a CD22-directed cytotoxin. It binds to CD22, a protein found on certain leukemia cells, and delivers a toxin that kills the cancer cells.
Lumoxiti is for adult patients with hairy cell leukemia who have already tried at least two treatments without successful results.
Lumoxiti is given as an intravenous (IV) infusion by a healthcare provider, typically on days 1, 3, and 5 of a 28-day cycle, for up to 6 cycles depending on response and tolerance.
Common side effects include swelling, nausea, fatigue, headache, fever, and infusion-related reactions.
Yes, Lumoxiti can cause serious side effects such as capillary leak syndrome (CLS), hemolytic uremic syndrome (HUS), kidney problems, and low blood counts. Report symptoms like sudden weight gain, low urine output, or swelling immediately.
Treatment usually continues for up to 6 cycles unless side effects become severe or the disease progresses. Your doctor will determine the duration based on your condition.
It’s best to avoid alcohol during treatment as it may stress your kidneys and liver, which are already monitored closely during Lumoxiti therapy.
No, Lumoxiti may harm an unborn baby. Effective contraception is recommended during treatment and for some time afterward.
Yes, Lumoxiti may interact with other medicines. Inform your healthcare provider about all the drugs and supplements you are taking.
Lumoxiti is administered by healthcare professionals. If you miss an appointment, contact your clinic immediately to reschedule the dose.
Lumoxiti is given by IV infusion, so food doesn’t directly impact its administration, but maintaining hydration is important during treatment.
Stay hydrated, watch for symptoms of serious side effects like fluid retention or kidney issues, and attend all scheduled blood and urine tests.
Lumoxiti is stored and prepared by healthcare providers in a medical facility; patients do not need to store it at home.
Lumoxiti is administered at specialized treatment centers or hospitals. Your oncologist will direct you to the appropriate facility for treatment. Pharma Five assists in its procurement.